Individualized Functional Imaging-Guided Repetitive Transcranial Magnetic Stimulation (rTMS) for Treating Postural Gait Disorders in Patients with Amyotrophic Lateral Sclerosis (ALS): a Randomized, Crossover, Controlled, Double-Blind Clinical Study

Exclusion Criteria

• •1. History of substance abuse within the past 6 months;
• •2. History of epilepsy or first-degree relative with epilepsy;
• •3. Patients with severe systemic diseases in the heart, lungs, liver, or kidneys that cannot be controlled with routine medications, based on laboratory results;
• •4. Patients with severe depression or anxiety (HAMD-17 score ≥18; HAMA score ≥21) or diagnosed with other mental illnesses;
• •5. Patients with a life expectancy of less than one year due to reasons other than neurodegenerative diseases;
• •6. Pregnant women or those planning to become pregnant;
• •7. Individuals with a pacemaker, cochlear implant, or other metallic foreign bodies and any implanted electronic equipment, or those with contraindications for MRI scanning or TMS treatment, such as claustrophobia;
• •8. Patients who have received TMS, transcranial electrical stimulation, transcranial focused ultrasound, or other neuromodulation treatments within three months prior to enrollment;
• •9. Other abnormal examination results deemed unsuitable for participation by the research investigator;
• •10. Inability to cooperate for follow-ups due to geographical or other reasons;
• •11. Participation in other clinical research trials.